Protocol Ledger

NCT03488524 · Phase II · COMPLETED

Open Label Extension Study of AMX0035 in Patients With ALS

Interventional Phase II clinical trial protocol NCT03488524 sponsored by Amylyx Pharmaceuticals in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-03-29 Enrollment: 90 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03488524
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)90 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03488524
Protocol FieldVerified Registry Value
NCT IdentifierNCT03488524
Consolidated Lead SponsorAmylyx Pharmaceuticals
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment90 participants (ACTUAL)
Registered Start Date2018-03-29
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI